DAPI in Fig. 4d and e, and the cells were viable and not
stained by PI as shown in Fig. 4f and g. These results show
that the probe has low cytotoxicity under these experimental
conditions.
To conclude, we have developed a NIR organoselenium
fluorescent probe for detecting ONOOꢀ and imaging of redox
cycles in living cells. BzSe-Cy is a unique small-molecule
indicator containing Se that responds reversibly to changes
in ONOOꢀ or ASCH2 concentration, and it exhibits high
sensitivity and selectivity for ONOOꢀ. Moreover, the new
probe was successfully applied to the imaging of multiple
cycles of oxidative stress and reductive repair in RAW 264.7
cells. This work provides a new approach to studying the
generation, metabolism of ONOOꢀ and its dynamic damage
process of living cells with related chemical tools.
Fig. 4 Confocal fluorescence images of living RAW 264.7 cells.
(a) Cells incubated with 20 mM BzSe-Cy at 37 1C for 30 min and then
incubated with 50 nM Mito Tracker Green FM for 10 min, using a
633 nm laser. (b) The above cells were excited by a 488 nm laser.
(c) One overlay image of (a) and (b). (d) Cells incubated with 20 mM
BzSe-Cy at 37 1C for 30 min and then incubated with 10 mg mLꢀ1
DAPI for 15 min, using a 405 nm laser. (e) One overlay image of
(d) and an image of the (d) cells excited by a 633 nm laser. (f) Cells
incubated with 20 mM BzSe-Cy at 37 1C for 30 min and then incubated
with 50 mg mLꢀ1 PI for 5 min, using a 543 nm laser. (g) One overlay
image of (f) and an image of the (f) cells excited by a 633 nm laser.
This work was supported by National Basic Research
Program of China (973 Program, 2007CB936000), National
Natural Science Funds (NNSF) for Distinguished Young
Scholar (No. 20725518), NNSF of China (No. 20875057),
National Key Natural Science Foundation of China (No.
21035003), Key Natural Science Foundation of Shandong
Province of China (ZR2010BZ001), and the Science and
Technology Development Programs of Shandong Province
of China (No. 2008GG30003012).
optimized in Fig. S6 (ESIw)), while a bright fluorescence was
again observed at the same field of view after addition of
50 mM ASCH2 into the medium and incubation for another
30 min at 37 1C (Fig. 3c). To further prove that BzSe-Cy has a
good reversibility, addition of a second aliquot of SIN-1
resulted in another decrease in intracellular fluorescence
(Fig. 3d), and when the same cells were incubated with ASCH2
again, the bright fluorescence appeared (Fig. 3e). The result
indicates that the fluorescence changes in the RAW 264.7 cells
are due to the changes in the intracellular ONOOꢀ levels, and
BzSe-Cy can also monitor the redox cycles in living cells. The
bright-field image (Fig. 3f) confirmed that the cells were
viable throughout the imaging experiments. In addition, the
internalization assay has been carried out both at 37 1C and
4 1C, proving that BzSe-Cy exhibits excellent cell membrane
permeability (Fig. S7, ESIw).
Furthermore, we assessed the ability of BzSe-Cy to target
the mitochondria in living cells. RAW 264.7 cells incubated
with 20 mM BzSe-Cy for 30 min at 37 1C showed bright
fluorescence in discrete subcellular locations as determined
by confocal microscopy (Fig. 4a). A co-staining experiment
with Mito Tracker Green FM (a commercially available
mitochondrial green-fluorescent probe) has been carried out
to establish that BzSe-Cy is localized to the mitochondria
(Fig. 4b). The overlay image confirms that the probe is
retained in the mitochondria of these living cells (Fig. 4c).
Finally, to further prove that BzSe-Cy has a low toxicity to the
cultured cell lines, the MTT assay (Fig. S8, ESIw) and nuclear
staining with 40,6-diamidino-2-phenylindole (DAPI, which
can stain both live and dead cells) and propidium iodide
(PI, which can only stain dead cells) were performed. The
experiments showed that the cell morphology was scatheless as
determined by comparison with the image of cells dyed with
Notes and references
1 M. Torresa and H. J. Forman, BioFactors, 2003, 17, 287.
2 W. Davis, Jr, Z. Ronai and K. D. Tew, J. Pharmacol. Exp. Ther.,
2001, 296, 1.
3 T. Lu, Y. Pan, S. Y. Kao, C. Li, I. Kohane, J. Chan and
B. A. Yankner, Nature, 2004, 429, 883.
4 J. K. Andersen, Nat. Med. (N. Y.), 2004, 10(suppl), S18.
5 (a) G. T. Hanson, R. Aggeler, D. Oglesbee, M. Cannon,
R. A. Capaldi, R. Y. Tsien and S. J. Remington, J. Biol. Chem.,
2004, 279, 13044; (b) V. V. Belousov, A. F. Fradkov,
K. A. Lukyanov, D. B. Staroverov, K. S. Shakhbazov,
A. V. Terskikh and S. Lukyanov, Nat. Methods, 2006, 3, 281.
6 (a) E. W. Miller, S. X. Bian and C. J. Chang, J. Am. Chem. Soc.,
2007, 129, 3458; (b) D. Srikun, A. E. Albers and C. J. Chang,
Chem. Sci., 2011, 2, 1156.
7 R. Radi, G. Peluffo, M. N. Alvarez and A. Cayota, Free Radical
Biol. Med., 2001, 30, 463.
8 J. S. Beckman, T. W. Beckman, J. Chen, P. A. Marshall and
B. A. Freeman, Proc. Natl. Acad. Sci. U. S. A., 1990, 87, 1620.
9 (a) D. Yang, H. Wang, Z. Sun, N. Chung and J. Shen, J. Am.
Chem. Soc., 2006, 128, 6004; (b) T. Peng and D. Yang, Org. Lett.,
2010, 12, 4932.
10 C. Song, Z. Ye, G. Wang, J. Yuan and Y. Guan, Chem.–Eur. J.,
2010, 16, 6464.
11 G. Mugesh, W. W. du Mont and H. Sies, Chem. Rev., 2001,
101, 2125.
12 H. Sies and H. Masumoto, Adv. Pharmacol., 1997, 38, 229.
13 (a) C. W. Nogueira, G. Zeni and J. B. T. Rocha, Chem. Rev., 2004,
104, 6255; (b) S. W. May, L. Wang, M. M. Gill-Woznichak,
R. F. Browner, A. A. Ogonowski, J. B. Smith and S. H. Pollock,
J. Pharmacol. Exp. Ther., 1997, 283, 470; (c) S. Padmaja,
G. L Squadrito, J. N. Lemercier, R. Cueto and W. A. Pryor, Free
Radical Biol. Med., 1996, 21, 317.
14 D. Wu, A. B. Descalzo, F. Weik, F. Emmerling, Z. Shen, X. You
and K. Rurack, Angew. Chem., Int. Ed., 2008, 47, 193.
15 D. Oushiki, H. Kojima, T. Terai, M. Arita, K. Hanaoka, Y. Urano
and T. Nagano, J. Am. Chem. Soc., 2010, 132, 2795.
16 C. Q. Li, L. J. Trudel and G. N. Wogan, Chem. Res. Toxicol., 2002,
15, 527.
c
9470 Chem. Commun., 2011, 47, 9468–9470
This journal is The Royal Society of Chemistry 2011